Effective April 15, patients may bring one visitor to an appointment.
Learn more about this and other COVID-19 related updates

Clinical Trials & Research

Ph1 CX-4945 Basal Cell Carcinoma

A Phase I, Multi-Center, Open-Label, Treatment Duration Increment, Expansion, Safety, and Pharmacodynamic Study of CX-4945 Administered Orally Twice Daily to Patients with Advanced Basal Cell Carcinoma (CX-4945-07)

Disease Types: Basal Cell Carcinoma,&nbs

Available at: {clinical_trial_location backspace="7"}Ph1 CX-4945 Basal Cell Carcinoma, {/clinical_trial_location}

Principal Investigator: {clinical_trial_principle_investi} , {/clinical_trial_principle_investi}